Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals

Bioanalysis

Volumn 4, Issue 17, 2012, Pages 2179-2190

  Tovey, Michael G ^a   Lallemand, Christophe ^a  

^a Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA INTERFERON; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; DNA; DRUG ANTIBODY; EPRIX; ERYTHROPOIETIN; ETANERCEPT; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERFERON BETA SERINE; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CARCINOID; CELL ASSAY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; CROHN DISEASE; DRUG DETERMINATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; HUMAN; IMMOBILIZED CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; REPORTER GENE; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; RNA ANALYSIS; STANDARDIZATION;

ANTIBODIES, NEUTRALIZING; BIOPHARMACEUTICS; CELL LINE, TUMOR; HUMANS;

EID: 84866939661     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.186     Document Type: Review

References (77)

1. Buttel IC, Chamberlain P, Chowers Y et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39(2), 100-109 (2011
2. Wadhwa M, Thorpe R. Unwanted immunogenicity: Lessons learned and future challenges. Bioanalysis 2(6), 1073-1084 (2011
3. Kirshner S. Immunogenicity of therapeutic proteins: A regulatory perspective. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley and Sons Inc., NY, USA 15-37 (2011
4. Ottesen JL, Nilsson P, Jami J et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37(12), 1178-1185 (1994 (Pubitemid 24356756)
5. Gribben JG, Devereux S, Thomas NS et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335(8687), 434-437 (1990 (Pubitemid 20054650)
6. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51(4), 691-697 (1980 (Pubitemid 10024715)
7. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118(1), 42-50 (2006
8. Hayakawa T, Ishii A. Japanese regulatory perspective on immunogenicity. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley and Sons Inc., NY, USA (2011
9. Ragnhammar P, Friesen HJ, Frodin JE et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84(12), 4078-4087 (1994
10. Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non- Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin. Cancer Res. 6(7), 2644-2652 (2000 (Pubitemid 30482099)
11. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000
12. Pijpe J, Van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-label Phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005 (Pubitemid 41369102)
13. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552-1563 (1998 (Pubitemid 28459913)
14. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008 (Pubitemid 351398485)
15. Farrell RA, Giovannoni G. Current and future role of interferon beta in the therapy of multiple sclerosis. J. Interferon Cytokine Res. 30(10), 715-726 (2010
16. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469-475 (2002 (Pubitemid 34441737)
17. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12), 3241-3248 (2001
18. Meager A, Dolman C, Dilger P et al. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J. Interferon Cytokine Res. 31(4), 383-392 (2011
19. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 80(1), 88-92 (2011
20. Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: You can't fool Mother Nature. Kidney Int. 80(1), 11-13 (2011
21. Casadevall N, Thorpe R, Schellekens H. Biosimilars need comparative clinical data. Kidney Int. 80(5), 553 (2011
22. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008
23. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25(5), 555-561 (2007 (Pubitemid 46834844)
24. Schneider CK, Papaluca M, Kurki P. A European perspective on immunogenicity evaluation. Nat. Biotechnol. 27(6), 507-508 (2009
25. Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54(2), 164-182 (2009
26. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008
27. Kramer D. Standardization and Validation of Immunoassays. John Wiley & Sons, NY, USA, 235 (2011
28. Novick D, NAbioullin RR, Ragsdale W et al. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation. J. Interferon Cytokine Res. 20(11), 971-982 (2000
29. Meager A. Measurement of cytokines by bioassays: Theory and application. Methods 38(4), 237-252 (2006
30. Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29(2), 56-66 (2005 (Pubitemid 39626637)
31. Wala I, Swanson SJ, Jing S. A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. J. Pharm. Biomed. Anal. 45(4), 583-589 (2007 (Pubitemid 350007949)
32. Kitamura T, Sekimata M, Kikuchi S, Homma Y. Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. Am. J. Physiol. Cell Physiol. 289(1), C82-C88 (2005 (Pubitemid 40880827)
33. Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods 308(1-2), 101-108 (2006 (Pubitemid 43107958)
34. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene 23(20), 3530- 3540 (2004 (Pubitemid 38658419)
35. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: The tenfold reduction unit. J. Interferon Cytokine Res. 21(9), 743-755 (2001 (Pubitemid 32955704)
36. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res. 21(9), 729-742 (2001 (Pubitemid 32955703)
37. Kawade Y, Finter N, Grossberg SE. Neutralization of the biological activity of cytokines and other protein effectors by antibody: Theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 278(1-2), 127-144 (2003 (Pubitemid 37281197)
38. Grossberg SE, Casey M, Grossberg LD. Quantification of the neutralization of cytokine biological activity by antibody: The ten-fold reduction bioassay of interleukin-6 as growth factor. J. Interferon Cytokine Res. 29(8), 421-426 (2009
39. Bertolotto A, Sala A, Caldano M et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J. Immunol. Methods 321(1-2), 19-31 (2007 (Pubitemid 46441209)
40. Moore M, Meager A, Wadhwa M, Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J. Pharm. Biomed. Anal. 49(2), 534-539 (2009
41. Lallemand C, Meritet JF, Erickson R et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res. 28(6), 393-404 (2008 (Pubitemid 351929939)
42. Gilli F, Bertoloto A. Immunogenicity of Therapeutic Proteins: A Regulatory Perspective. Tovey MG (Ed.). John Wiley and Sons Inc, NY, USA, 157-174 (2011
43. Liang M, Klakamp SL, Funelas C et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5(5), 655-662 (2007
44. Loyet KM, Deng R, Liang WC, Wu Y, Lowman HB, Deforge LE. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 345(1-2), 17-28 (2009
45. Aarskog NK, Maroy T, Myhr KM, Vedeler CA. Antibodies against interferon-beta in multiple sclerosis. J. Neuroimmunol. 212(1-2), 148-150 (2009
46. Meager A. Biological assays for interferons. J. Immunol. Methods 261(1-2), 21-36 (2002 (Pubitemid 34175214)
47. Lam R, Farrell R, Aziz T et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN-beta in multiple sclerosis patients. J. Immunol. Methods 336(2), 113-118 (2008
48. Seo YJ, Kim GH, Kwak HJ et al. Validation of a HeLa Mx2/Luc reporter cell line for the quantification of human type I interferons. Pharmacology 84(3), 135-144 (2009
49. Lallemand C, Kavrochorianou N, Steenholdt C et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF-alpha antagonists. J. Immunol. Methods 373(1-2), 229-239 (2011
50. Lallemand C, Meritet JF, Blanchard B, Lebon P, Tovey MG. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J. Immunol. Methods 356(1-2), 18-28 (2010
51. Grossberg SE, Kawade Y, Grossberg LD. The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J. Interferon. Cytokine Res. 29(2), 93-104 (2009
52. Keating GM. Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70(11), 1445-1476 (2010
53. Tak PP, Rigby WF, Rubbert-Roth A et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial. Ann. Rheum. Dis. 70(1), 39-46 (2011
54. Coyle PK. The role of natalizumab in the treatment of multiple sclerosis. Am. J. Managed Care 16(6 Suppl.), S164-S170 (2010
55. Schweighofer CD, Wendtner CM. First-line treatment of chronic lymphocytic leukemia: Role of alemtuzumab. Onco. Targets Ther. 3, 53-67 (2010
56. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786-1801 (2008
57. Lee TW, Fedorak RN. Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: Clinical practice pharmacology. Gastroenterol. Clin. North Am. 39(3), 543-557 (2010
58. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376(9746), 1094-1108 (2010
59. Furst DE, Keystone EC, Braun J et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann. Rheum. Dis. 70(Suppl. 1), I2-I36 (2011
60. Pungor E Jr, Files JG, Gabe JD et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J. Interferon Cytokine Res. 18(12), 1025-1030 (1998 (Pubitemid 29011609)
61. Mckay F, Schibeci S, Heard R, Stewart G, Booth D. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort. J. Immunol. Methods 310(1-2), 20-29 (2006 (Pubitemid 43375972)
62. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult. Scler. 13(2), 208-214 (2007 (Pubitemid 46592773)
63. Shtalrid M, Lugassy G, Rosensaft J, Berrebi A. Treatment of chronic myeloid leukemia with interferon alpha (Roferon®): Results of the Israeli Study Group on CML. Leukemia Lymphoma 11(Suppl. 1), 193-197 (1993
64. Oberg K, Alm G. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 10(1), 1-5 (1997 (Pubitemid 27300145)
65. Von Wussow P, Hehlmann R, Hochhaus T et al. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia. J. Interferon Res. 14(4), 217-219 (1994 (Pubitemid 24292481)
66. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56(12), 1628-1636 (2001
67. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J. Interferon Cytokine Res. 31(3), 337-344 (2011
68. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59(10), 1496-1506 (2002 (Pubitemid 35387053)
69. Rudick RA, Simonian NA, Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50(5), 1266-1272 (1998 (Pubitemid 28240338)
70. Reder AT, Ebers GC, Traboulsee A et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 74(23), 1877-1885 (2010
71. Hartung HP, Freedman MS, Polman CH et al. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 77(9), 835-843 (2011
72. Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP et al. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Intl 68(3), 1215-1222 (2005 (Pubitemid 43246439)
73. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 60(8), 2541-2542 (2009
74. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin. Immunol. 118(1), 11-19 (2006 (Pubitemid 43012041)
75. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54(12), 3782-3789 (2006 (Pubitemid 44955878)
76. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review. Am. J. Clin. Dermatol. 8(3), 143-155 (2007 (Pubitemid 46998542)
77. Ullenhag G, Bird C, Ragnhammar P et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin. Immunol. 99(1), 65-74 (2001